Search

Your search keyword '"Lechtman S"' showing total 41 results
Start Over Author "Lechtman S"
41 results on '"Lechtman S"'

2. Un véritable piège artériel

Author

Bernigaud, C., primary, Barthelemy, G., additional, Caron, J., additional, Fassbender, V., additional, Jean-Baptiste, E., additional, Ottavi, M., additional, Lechtman, S., additional, Jeandel, P.Y., additional, Nihal, M., additional, Levraut, M., additional, and Merindol, J., additional

Published
2024
Full Text
View/download PDF

3. Une allogreffe sanglante

Author

Barthelemy, G., primary, Lechtman, S., additional, Jeandel, P.Y., additional, Ottavi, M., additional, Bernigaud, C., additional, Caron, J., additional, Martis, N., additional, Merindol, J., additional, and Levraut, M., additional

Published
2024
Full Text
View/download PDF

4. Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicentre retrospective case-control study

Author

Culerrier, J, Nguyen, Y, Karadag, O, Yasar Bilge, S, Demirci Yıldırım, T, Saygin Ögüt, T, Yazisiz, V, Bes, C, Celfe, A, Yazici, A, Sadioglu Cagdas, O, Kronbichler, A, Jayne, D, Gauckler, P, Regent, A, Teixeira, V, Marchand-Adam, S, Duffau, P, Ingen-Housz-Oro, S, Droumaguet, C, Andre, B, Luca, L, Lechtman, S, Aouba, A, Lebas, C, Servettaz, A, Dernoncourt, A, Ruivard, M, Milesi, A, Poindron, V, Jego, P, Padoan, R, Delvino, P, Vandergheynst, F, Pagnoux, C, Yacyshyn, E, Lamprecht, P, Flossmann, O, Puéchal, X, Terrier, B, Julien Culerrier, Yann Nguyen, Omer Karadag, Sule Yasar Bilge, Tuba Demirci Yıldırım, Tahir Saygin Ögüt, Veli Yazisiz, Cemal Bes, Ayse Celfe, Ayten Yazici, Oznur Sadioglu Cagdas, Andreas Kronbichler, David Jayne, Philipp Gauckler, Alexis Regent, Vitor Teixeira, Sylvain Marchand-Adam, Pierre Duffau, Saskia Ingen-Housz-Oro, Celine Droumaguet, Baptiste Andre, Luminita Luca, Sarah Lechtman, Achille Aouba, Celine Lebas, Amélie Servettaz, Amandine Dernoncourt, Marc Ruivard, Anne-Marie Milesi, Vincent Poindron, Patrick Jego, Roberto Padoan, Paolo Delvino, Frédéric Vandergheynst, christian pagnoux, Elaine Yacyshyn, Peter Lamprecht, Oliver Flossmann, Xavier Puéchal, Benjamin Terrier, Culerrier, J, Nguyen, Y, Karadag, O, Yasar Bilge, S, Demirci Yıldırım, T, Saygin Ögüt, T, Yazisiz, V, Bes, C, Celfe, A, Yazici, A, Sadioglu Cagdas, O, Kronbichler, A, Jayne, D, Gauckler, P, Regent, A, Teixeira, V, Marchand-Adam, S, Duffau, P, Ingen-Housz-Oro, S, Droumaguet, C, Andre, B, Luca, L, Lechtman, S, Aouba, A, Lebas, C, Servettaz, A, Dernoncourt, A, Ruivard, M, Milesi, A, Poindron, V, Jego, P, Padoan, R, Delvino, P, Vandergheynst, F, Pagnoux, C, Yacyshyn, E, Lamprecht, P, Flossmann, O, Puéchal, X, Terrier, B, Julien Culerrier, Yann Nguyen, Omer Karadag, Sule Yasar Bilge, Tuba Demirci Yıldırım, Tahir Saygin Ögüt, Veli Yazisiz, Cemal Bes, Ayse Celfe, Ayten Yazici, Oznur Sadioglu Cagdas, Andreas Kronbichler, David Jayne, Philipp Gauckler, Alexis Regent, Vitor Teixeira, Sylvain Marchand-Adam, Pierre Duffau, Saskia Ingen-Housz-Oro, Celine Droumaguet, Baptiste Andre, Luminita Luca, Sarah Lechtman, Achille Aouba, Celine Lebas, Amélie Servettaz, Amandine Dernoncourt, Marc Ruivard, Anne-Marie Milesi, Vincent Poindron, Patrick Jego, Roberto Padoan, Paolo Delvino, Frédéric Vandergheynst, christian pagnoux, Elaine Yacyshyn, Peter Lamprecht, Oliver Flossmann, Xavier Puéchal, and Benjamin Terrier

Abstract

Objective: Data on ANCA-associated vasculitis (AAV) induced by anti-thyroid drugs (ATD) are scarce. We aimed to describe the characteristics and outcome of these patients in comparison to primary AAV. Methods: We performed a retrospective multicentre study including patients with ATD-induced AAV. We focused on ATD-induced microscopic polyangiitis (MPA) and compared them with primary MPA by matching each case with four controls by gender and year of diagnosis. Results: Forty-five patients with ATD-induced AAV of whom 24 MPA were included. ANCA were positive in 44 patients (98%), including myeloperoxidase (MPO)-ANCA in 21 (47%), proteinase 3 (PR3)-ANCA in six (13%), and double positive MPO- and PR3-ANCA in 15 (33%). Main clinical manifestations were skin involvement (64%), arthralgia (51%) and glomerulonephritis (20%). ATD was discontinued in 98% of cases, allowing vasculitis remission in seven (16%). All the remaining patients achieved remission after glucocorticoids, in combination with rituximab in 11 (30%) or cyclophosphamide in four (11%). ATD were reintroduced in seven cases (16%) without any subsequent relapse. Compared with 96 matched primary MPA, ATD-induced MPA were younger at diagnosis (48 vs 65 years, P < 0.001), had more frequent cutaneous involvement (54 vs 25%, P 1⁄4 0.007), but less frequent kidney (38 vs 73%, P 1⁄4 0.02), and a lower risk of relapse (adjusted HR 0.07; 95% CI 0.01, 0.65, P 1⁄4 0.019). Conclusion: ATD-induced AAV were mainly MPA with MPO-ANCA, but double MPO- and PR3-ANCA positivity was frequent. The most common manifestations were skin and musculoskeletal manifestations. ATD-induced MPA were less severe and showed a lower risk of relapse than primary MPA.

Published
2024

5. Artérite temporale révélant une maladie à éosinophiles : étude rétrospective multicentrique européenne

Author

Merindol, J., primary, Groh, M., additional, Arlet, J.B., additional, Lechtman, S., additional, Allain, J.S., additional, Boucaud, A., additional, Campagne, J., additional, Catros, F., additional, Coutard, A., additional, Durel, C.A., additional, Ebbo, M., additional, Kouchit, Y., additional, Lefevre, G., additional, Liozon, E., additional, Maurier, F., additional, Melboucy Belhkir, S., additional, Miranda, S., additional, Parreau, S., additional, Pestre, V., additional, Pouchot, J., additional, Rosenstingl, S., additional, Souchaud-Debouverie, O., additional, Xavier, P., additional, and Terrier, B., additional

Published
2023
Full Text
View/download PDF

7. Caractéristiques et évolution des vascularites associées aux ANCA induites par les antithyroïdiens de synthèse comparativement aux formes primitives : étude rétrospective multicentrique

Author

Culerrier, J., primary, Nguyen, Y., additional, Karadag, O., additional, Yasar Bilge, S., additional, Kronbichler, A., additional, Jayne, D., additional, Régent, A., additional, Teixeira, V., additional, Marchand-Adam, S., additional, Duffau, P., additional, Oro, S., additional, Droumaguet, C., additional, Andre, B., additional, Luca, L., additional, Lechtman, S., additional, Aouba, A., additional, Lebas, C., additional, Servettaz, A., additional, Puéchal, X., additional, and Terrier, B., additional

Published
2022
Full Text
View/download PDF

31. Un myélome gras, à propos d’un cas

Author

Lechtman, S., primary, Belenotti, P., additional, Queyrel, V., additional, Tieulie, N., additional, Hiéronimus, S., additional, Sassolas, A., additional, Versini, M., additional, Narbonne, H., additional, Serratrice, J., additional, and Fuzibet, J.-G., additional

Published
2012
Full Text
View/download PDF

34. Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab.

Author

Trefond L, Chasset F, Jachiet M, Livideanu C, Barba T, Faguer S, Henry J, Richard-Colmant G, Ferreira-Maldent N, Roque S, Monteiro R, Chevalier K, Lanteri A, Lazaro E, Scherlinger M, Belhomme N, Richez C, Cazalets C, Sailler L, Abdallah NA, de La Rochefoucauld J, Campagne J, Audemard A, Moulinet T, Abisror N, Costedoat-Chalumeau N, Lesort C, Bessis D, Kottler D, Saint-Pastou Terrier C, Jeandel PY, Lechtman S, Grolleau C, Hadjadj J, Pereira B, Smets P, André M, Bouaziz JD, Mathian A, and Amoura Z

Abstract

Competing Interests: Competing interests: LT received support for attending meetings and/or travel from GSK, AstraZeneca, Otsuka and CSL VIFOR. FC has received grant/research support from AstraZeneca, BMS and GSK; participated in an advisory board related to lupus for AstraZeneca, GSK, Celgene, Merck, Horizon Therapeutics and Principabio; and received speaking fees and honoraria from AstraZeneca and GSK BMS related to lupus. AM has received grant/research support from Sobi; participated in advisory board related to lupus for AstraZeneca; received payment for expert testimony for GSK; received support for attending meetings and/or travel from AstraZeneca, GSK, Novartis and Otsuka; and received consulting fees, speaking fees and honoraria from AstraZeneca, GSK, Novartis and Otsuka. ZA has received grant/research support from GSK, AstraZeneca, Roche, Novartis and Amgen; participated in advisory board related to lupus for GSK, AstraZeneca, Kezar, Amgen, Otsuka, Novartis; and received consulting fees, speaking fees and honoraria from AstraZeneca and GSK. MJ participated in an advisory board and received speaking fees from AstraZeneca and GSK related to lupus. JLR received support for attending meetings and/or travel from GSKNB has participated in an advisory board related to lupus for AstraZeneca and received speaking fees and honoraria from AstraZeneca and GSK related to lupus. NCC participated in an advisory board related to lupus for BMS and received a grant to her institution from Roche and AstraZeneca. SF has participated in an advisory board for CSL Vifor, Sanofi – Genzyme, Novartis, Alexion and AstraZeneca. EL has received a grant/research support from AstraZeneca, SOBI, NOVARTIS and GSK; participated in an advisory board related to lupus for AstraZeneca and GSK; and received speaking fees and honoraria from AstraZeneca and GSK BMS related to lupus. MA received support for attending meetings and/or travel from Novartis and CSL VIFOR. JDB received consulting fees, speaking fees and grants from Astra Zeneca. CSPT received support for attending meetings and/or travel from AstraZeneca, GSK, Novartis and Abbvie. MS is a consultant for Abbvie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Fresenius Kabi, Galapagos, Innate Pharma, Nordic Pharma, Novartis and Sandoz. CL received speaking fees from GSK, Astrazenaca and BMSCR and has acted as a consultant for Abbvie, AstraZeneca, Biogen, BMS, GSK, Lilly, Novartis, and Pfizer.

Published
2025
Full Text
View/download PDF

35. Characteristics and outcome of ANCA-associated vasculitides induced by anti-thyroid drugs: a multicentre retrospective case-control study.

Author

Culerrier J, Nguyen Y, Karadag O, Yasar Bilge S, Yildrim TD, Ögüt TS, Yazisiz V, Bes C, Celfe A, Yazici A, Sadioglu Cagdas O, Kronbichler A, Jayne D, Gauckler P, Regent A, Teixeira V, Marchand-Adam S, Duffau P, Housz-Oro SI, Droumaguet C, Andre B, Luca L, Lechtman S, Aouba A, Lebas C, Servettaz A, Dernoncourt A, Ruivard M, Milesi AM, Poindron V, Jego P, Padoan R, Delvino P, Vandergheynst F, Pagnoux C, Yacyshyn E, Lamprecht P, Flossmann O, Puéchal X, and Terrier B

Subjects
Humans, Retrospective Studies, Antibodies, Antineutrophil Cytoplasmic, Case-Control Studies, Myeloblastin, Recurrence, Peroxidase, Granulomatosis with Polyangiitis diagnosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis drug therapy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis diagnosis, Microscopic Polyangiitis
Abstract

Objective: Data on ANCA-associated vasculitis (AAV) induced by anti-thyroid drugs (ATD) are scarce. We aimed to describe the characteristics and outcome of these patients in comparison to primary AAV., Methods: We performed a retrospective multicentre study including patients with ATD-induced AAV. We focused on ATD-induced microscopic polyangiitis (MPA) and compared them with primary MPA by matching each case with four controls by gender and year of diagnosis., Results: Forty-five patients with ATD-induced AAV of whom 24 MPA were included. ANCA were positive in 44 patients (98%), including myeloperoxidase (MPO)-ANCA in 21 (47%), proteinase 3 (PR3)-ANCA in six (13%), and double positive MPO- and PR3-ANCA in 15 (33%). Main clinical manifestations were skin involvement (64%), arthralgia (51%) and glomerulonephritis (20%). ATD was discontinued in 98% of cases, allowing vasculitis remission in seven (16%). All the remaining patients achieved remission after glucocorticoids, in combination with rituximab in 11 (30%) or cyclophosphamide in four (11%). ATD were reintroduced in seven cases (16%) without any subsequent relapse. Compared with 96 matched primary MPA, ATD-induced MPA were younger at diagnosis (48 vs 65 years, P < 0.001), had more frequent cutaneous involvement (54 vs 25%, P = 0.007), but less frequent kidney (38 vs 73%, P = 0.02), and a lower risk of relapse (adjusted HR 0.07; 95% CI 0.01, 0.65, P = 0.019)., Conclusion: ATD-induced AAV were mainly MPA with MPO-ANCA, but double MPO- and PR3-ANCA positivity was frequent. The most common manifestations were skin and musculoskeletal manifestations. ATD-induced MPA were less severe and showed a lower risk of relapse than primary MPA., (© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

36. Incidence of giant cell arteritis in six districts of Paris, France (2015-2017).

Author

Gonzalez Chiappe S, Lechtman S, Maldini CS, Mekinian A, Papo T, Sené T, and Mahr AD

Subjects
Aged, Aged, 80 and over, Databases, Factual, Female, France epidemiology, Humans, Incidence, Male, Middle Aged, Prospective Studies, Giant Cell Arteritis diagnosis, Giant Cell Arteritis epidemiology
Abstract

This prospective population-based study estimated the incidence of giant cell arteritis (GCA) in northeastern Paris. GCA cases diagnosed between 2015 and 2017 were obtained from local hospital and community-based physicians and the national health insurance system database. Criteria for inclusion were living in the study area at that time and fulfilling the 1990 American College of Rheumatology classification criteria and/or its expanded version. Cranial and large-vessel GCA cases were defined by the presence or absence of cranial signs and/or symptoms, respectively. Annual incidence was calculated by dividing the number of incident cases by the size of the study population ≥ 50 years old. Completeness of case ascertainment was assessed by a three-source capture-recapture analysis. Among the 62 included cases, 42 (68%) were women, mean (± SD) age 77.3 ± 9.1 years. The annual incidence of GCA in northeastern Paris and completeness of case ascertainment were estimated at 7.6 (95% CI 5.9-9.8) per 100,000 inhabitants ≥ 50 years old and 66% (95% CI 52-92%), respectively. Incidence increased with age, peaked at age 80-89 years, and was almost twice as high in women versus men. Large-vessel GCA cases, mean (± SD) age 68.6 ± 11.5 years, accounted for 8% of all GCA cases. In this study, GCA epidemiology was mainly driven by cases with cranial GCA signs or symptoms and incidence results were consistent with recent European and past French studies., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Published
2022
Full Text
View/download PDF

37. Immune thrombocytopenic purpura after COVID-19 infection.

Author

Levraut M, Ottavi M, Lechtman S, Mondain V, and Jeandel PY

Subjects
COVID-19 complications, COVID-19 virology, Female, Humans, Middle Aged, Purpura, Thrombocytopenic, Idiopathic complications, Purpura, Thrombocytopenic, Idiopathic immunology, SARS-CoV-2 physiology, COVID-19 diagnosis, Purpura, Thrombocytopenic, Idiopathic diagnosis, SARS-CoV-2 isolation & purification
Published
2021
Full Text
View/download PDF

38. Cerebral Amyloid Angiopathy Related Inflammation With Prominent Meningeal Involvement. A Report of 2 Cases.

Author

Aghetti A, Sène D, Polivka M, Shor N, Lechtman S, Chabriat H, Jouvent E, and Guey S

Abstract

Cerebral amyloid angiopathy related inflammation (CAA-RI) is a rare form of CAA characterized by subacute encephalitic symptoms (cognitive decline, seizures, focal deficits) associated with extensive and confluent white matter lesions co-localizing with lobar microbleeds on brain MRI. We report two cases of unusual CAA-RI mimicking meningoencephalitis but without typical brain lesions on FLAIR and T2 * sequences. These 2 cases may extend the clinical spectrum of CAA-RI by suggesting the possible occurrence of quite purely meningeal forms of CAA-RI., (Copyright © 2019 Aghetti, Sène, Polivka, Shor, Lechtman, Chabriat, Jouvent and Guey.)

Published
2019
Full Text
View/download PDF

40. Cystic lung disease in Sjögren's syndrome: An observational study.

Author

Lechtman S, Debray MP, Crestani B, Bancal C, Hourseau M, Dossier A, Alexandra JF, Chauveheid MP, Papo T, and Sacre K

Subjects
Aged, Female, Humans, Lung Diseases etiology, Male, Middle Aged, Tomography, X-Ray Computed, Lung Diseases diagnostic imaging, Sjogren's Syndrome complications
Abstract

Objectives: To analyze the prevalence, characteristics and outcome of cystic lung disease associated with Sjögren's syndrome (SS)., Methods: From June 2010 to February 2015, 90 consecutive SS patients [60.1±14.8years; 88 (97.8%) female, 75 (83.3%) primary SS] had a systematic chest CT-scan. The presence of thin-walled cysts was analyzed by one experienced radiologist. Demographic data, clinical history, laboratory findings, and pulmonary function tests were extracted retrospectively from medical records., Results: Twenty-one (23.3%) patients had cysts on CT scan performed 40.5±54.5months after SS diagnosis. Cysts number ranged from 1 to 25 were often bilateral (52.4%) and mostly located in the middle lung zone (76.2%). Cysts were isolated (n=6, 28.6%) or associated with other lesions, including bronchiectasis (n=5, 23.8%), micronodules (n=5, 23.8%), ground-glass opacity (n=4, 19%) and/or air trapping (n=3, 14.3%). Most patients with cysts (57.1%) had no respiratory symptoms. When comparing SS patients with and without cysts, patients with cysts tended to be older (65.3±15.3 versus 58.5±14.4years, P=0.06). Smoking habits were similar in both groups. Anti-SSB antibodies were more frequently detected in patients with cysts (57.1% vs. 26.1%, P=0.02). Pulmonary function tests were normal or displayed only mild small airways obstruction and reduced diffusion capacity to carbon monoxide. Four (19%) patients with cysts had a past history of associated pulmonary disease, including interstitial lung disease. During follow-up (25.1±17.7months), no patient developed specific lung disease or lymphoproliferative disorders., Conclusions: Cystic lung disease is frequent, benign, associated with anti-SSB/La antibodies and has no impact on outcome in SS., (Copyright © 2016 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.)

Published
2017
Full Text
View/download PDF

41. A therapeutic challenge: catastrophic anti-phospholipid syndrome with diffuse alveolar haemorrhage.

Author

Martis N, Blanchouin E, Lazdunski R, Lechtman S, Robert A, Hyvernat H, Doyen D, Dellamonica J, and Bernardin G

Subjects
Anticoagulants administration & dosage, Antiphospholipid Syndrome diagnosis, Female, Glucocorticoids administration & dosage, Hemorrhage diagnosis, Humans, Immunoglobulins, Intravenous administration & dosage, Lung Diseases diagnosis, Middle Aged, Plasma Exchange, Tomography, X-Ray Computed, Treatment Outcome, Antiphospholipid Syndrome complications, Hemorrhage etiology, Hemorrhage therapy, Lung Diseases etiology, Lung Diseases therapy
Abstract

Diffuse alveolar haemorrhage (DAH) complicating primary catastrophic anti-phospholipid syndrome (CAPS) was diagnosed in a 50-year-old female patient. Treatment strategies are limited for this often life-threatening autoimmune disease that requires aggressive immunosuppression. In the absence of clinically validated treatment strategies, high-dose steroids associated with plasma exchange and eventually intravenous immunoglobulins were used to manage the disease. Its severity prompted the initiation of rituximab that was administered weekly for four consecutive weeks. Anticoagulation therapy, on the other hand, needed to be discontinued due to the major haemorrhagic episodes. This combination treatment provided an effective control of the CAPS-associated DAH and helped achieve clinical remission.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results